C12R2001/36

MENINGOCOCCAL B RECOMBINANT VACCINE

The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

ULTRAFILTRATION FOR PREPARING OUTER MEMBRANE VESICLES

In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of ultrafiltration. The ultrafiltration step is performed on an aqueous suspension of OMVs after they have been prepared from bacteria and the OMVs remain in suspension after the filtration step. The invention is particularly useful for preparing OMVs from Neisseria meningitidis.

Ultrafiltration for preparing outer membrane vesicles

In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilizes ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of ultrafiltration. The ultrafiltration step is performed on an aqueous suspension of OMVs after they have been prepared from bacteria and the OMVs remain in suspension after the filtration step. The invention is particularly useful for preparing OMVs from Neisseria meningitidis.

Bacterium and extracts of said bacterium and the use of same in dermatology

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

A NOVEL DOWNSTREAM PROCESS FOR PURIFYING POLYSACCHARIDES

The present invention relates to a novel process for purifying bacterial polysaccharide. It is an efficient and scalable process for removing impurities from Neisseria meningitidis serogroup C (Men-C) polysaccharide which is capable of being used as such in a derivatized form or linked to other molecules, for the preparation of vaccines, more particularly conjugate vaccines for N. meningitidis infection.

MICROORGANISM HAVING IMPROVED 3'-SIALYLLACTOSE PRODUCTIVITY AND PRODUCTION METHOD OF 3'-SIALYLLACTOSE

The present invention relates to a microorganism having an enhanced activity of a protein consisting of an amino acid sequence in which N-terminus 20 to 37 amino acid residues in the amino acid sequence represented by SEQ ID NO: 2 are deleted, where the microorganism has improved productivity of 3-sialyllactose as compared with that of a parent strain.